Oral News and Research

RSS

AVMA confirms that a household cat in Iowa showed signs of H1N1 influenza

Amarillo Biosciences, Inc. reported that the American Veterinary Medical Association (AVMA) recently confirmed that a household cat in Iowa developed signs of respiratory infection caused by H1N1 influenza virus.

12 Nov 2009

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Allos Therapeutics, Inc. today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009.

12 Nov 2009

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three-month and nine-month periods ended September 30, 2009.

11 Nov 2009

Fort Hood shootings: Oral and maxillofacial surgeons among first responders

Before news of the November 5, Fort Hood shootings reached the public, oral and maxillofacial surgeons Major Mark E. Ranschaert, DMD and Major Joseph Dylan Bowles, DDS were in Fort Hood's Carl R. Darnall Army Medical Center emergency room working to save the lives of the shooter's victims.

11 Nov 2009

Potential benefits of Labopharm's novel trazodone formulation published

Labopharm Inc. today announced an article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009 issue, citing the potential benefit of its novel trazodone formulation, which contains Contramid(R). Labopharm's Contramid is the clinically validated proprietary technology that controls the release of active substances from oral medications to optimize drug delivery.

11 Nov 2009

Majority of pharmacists say patients should use OTC drugs at the first sign of cold and flu symptoms

A recent national survey of 505 pharmacists found that nine out of 10 pharmacists believe it is important for a patient to seek treatment early to help shorten the duration and severity of a cold.

11 Nov 2009

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals, Inc. today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data from the carfilzomib development program in patients with relapsed and refractory multiple myeloma.

11 Nov 2009

Tips for treating age-related dermatologic concerns

Everyone expects their bodies to change as they get older. From wrinkles and sagging skin to brittle bones and aches and pains, the aging process is inevitable. In addition, there are a number of medical dermatologic conditions that surface with age that can cause people even more stress. Fortunately, dermatologists can help diagnose and treat these conditions no matter when they strike.

11 Nov 2009

Online community launched to help families affected by PTSD

Since the Vietnam Era, the American psychiatric community has recognized the returning war veterans’ affliction of what is now commonly known as Post Traumatic Stress Disorder (PTSD).

11 Nov 2009

SMI Manufacturing to invest $10 million in HealthSport

HealthSport, Inc., the preeminent formulator and developer of edible, multi-layer film strips that deliver drug and dietary supplement actives through buccal and sublingual absorption as well as oral ingestion, announced today that its strategic manufacturing partner, SMI Manufacturing, has agreed to invest $10 million into HealthSport.

11 Nov 2009

Colorcon acquires exclusive rights to market ARmark's micro-tag authentication technology

ARmark Authentication Technologies, LLC, and Colorcon, Inc. announced today an alliance in the development and introduction of ®mark® On-Dose ID(TM), an authentication technology that incorporates microscopic covert micro-tags into the immediate-release film coatings of solid oral dosage forms (SODFs) to prevent counterfeiting.

10 Nov 2009

Cerimon Pharmaceuticals acquires rights to develop and commercialize diclofenac sodium patch in Europe

Cerimon Pharmaceuticals, Inc., announced today that it has acquired exclusive rights to develop and commercialize its once-daily topical diclofenac sodium patch in Europe, including most countries in the European Union, Turkey, Switzerland, Norway, the Balkan countries and Iceland. Terms of the agreement were not disclosed. Cerimon initially acquired the U.S. rights to develop and commercialize the patch formulation of diclofenac in 2005.

10 Nov 2009

Enavail obtains an exclusive license for a portfolio of particle engineering technologies

Particle engineering company Enavail announced today that it has obtained an exclusive license from The University of Texas at Austin for a portfolio of particle engineering technologies that will be utilized for pharmaceutical, biotechnology and nutraceutical applications.

10 Nov 2009

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer.

9 Nov 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Cardiome Pharma announces financial results for the three months ended September 30, 2009

Cardiome Pharma Corp. today reported financial results for the third quarter ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

9 Nov 2009

Thomson Reuters releases CareFocus 2.0 clinical surveillance solution

Thomson Reuters today announced the newest release of Clinical Xpert(TM) CareFocus, a leading clinical surveillance solution that enables hospitals to identify at-risk patients in real-time and respond immediately to improve clinical quality and reduce total cost of treatment.

9 Nov 2009

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

GTx reports financial results for the third quarter of 2009

GTx, Inc. today reported financial results for the third quarter of 2009. The net loss for the third quarter and nine months ended September 30, 2009 was $12.8 million and $35.4 million, respectively, compared with a net loss of $11.9 million and $37.9 million for the same periods in 2008. At September 30, 2009 GTx had cash, cash equivalents and short-term investments of $55.5 million.

9 Nov 2009

Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor

Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection. In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the company’s strategic alliance with GlaxoSmithKline.

9 Nov 2009

Oral News and Research

AVMA confirms that a household cat in Iowa showed signs of H1N1 influenza

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

Fort Hood shootings: Oral and maxillofacial surgeons among first responders

Potential benefits of Labopharm's novel trazodone formulation published

Majority of pharmacists say patients should use OTC drugs at the first sign of cold and flu symptoms

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Tips for treating age-related dermatologic concerns

Online community launched to help families affected by PTSD

SMI Manufacturing to invest $10 million in HealthSport

Colorcon acquires exclusive rights to market ARmark's micro-tag authentication technology

Cerimon Pharmaceuticals acquires rights to develop and commercialize diclofenac sodium patch in Europe

Enavail obtains an exclusive license for a portfolio of particle engineering technologies

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Cardiome Pharma announces financial results for the three months ended September 30, 2009

Thomson Reuters releases CareFocus 2.0 clinical surveillance solution

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

GTx reports financial results for the third quarter of 2009

Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News